Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Guo X, Barroso L, Lyerly DM, Petri WA Jr, Houpt ER.

Vaccine. 2011 Jan 17;29(4):772-7. doi: 10.1016/j.vaccine.2010.11.013. Epub 2010 Nov 21.

PMID:
21095257
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Adherence-blocking vaccine for amebiasis.

Petri WA Jr, Chaudhry O, Haque R, Houpt E.

Arch Med Res. 2006 Feb;37(2):288-91. Review.

PMID:
16380334
[PubMed - indexed for MEDLINE]
3.

Opportunities and obstacles in developing a vaccine for Entamoeba histolytica.

Miller-Sims VC, Petri WA Jr.

Curr Opin Immunol. 2002 Oct;14(5):549-52. Review.

PMID:
12183151
[PubMed - indexed for MEDLINE]
4.

Progress towards development of a vaccine for amebiasis.

Stanley SL Jr.

Clin Microbiol Rev. 1997 Oct;10(4):637-49. Review.

PMID:
9336666
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis.

Brod SA, Nelson LD, Khan M, Wolinsky JS.

Int J Neurosci. 1997 Aug;90(3-4):187-202. Review.

PMID:
9352427
[PubMed - indexed for MEDLINE]
6.

Entamoeba histolytica: from adherence to enteropathy.

Ravdin JI.

J Infect Dis. 1989 Mar;159(3):420-9. Review.

PMID:
2536786
[PubMed - indexed for MEDLINE]
7.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk